Registration will open soon for the Biomedical Advanced Research and Development Authority’s (“BARDA”) 2018 Industry Day to be held on October 29 and 30 at the Grand Hyatt in Washington, D.C. This event has been an integral part of BARDA’s outreach efforts to the life sciences community since 2007, and the newest version of this event promises to continue to provide meaningful insight into BARDA’s role in the nation’s public health preparedness efforts.

BARDA is expected to revisit annual topics like revisions to its broad agency announcement and updates to its goals and Government-wide strategic plans. In addition, this year BARDA will have a particular focus on innovation with the rollout of its Division of Research, Innovation, and Ventures (“DRIVe”) and lightning talks on noteworthy development efforts. Applications to participate in lightning talks are due soon, and potential participants should consider whether to take advantage of this unique opportunity.

Background

BARDA was formed at the end of 2006 with the passage of the Pandemic and All-Hazards Preparedness Act. Less than one year later, BARDA held its first Industry Day and has increasingly become a focal point in public health preparedness with the passage of the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 and the 21st Century Cures Act. BARDA’s role is expected to continue to expand once the Senate and House versions of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 are reconciled and passed in a final form later this year.

Current Authorities

Currently, BARDA has significant flexibility to enter into novel relationships to promote countermeasure development and procurement efforts. For example, BARDA has previously taken advantage of a countermeasure-based antitrust exemption to support collaborative studies among competing vaccine manufacturers. In addition, BARDA has to date entered into six high-value other transaction authority agreements (“OTA”), which are not subject to many of the rigid requirements that apply to standard procurement contracts, grants, and cooperative agreements. BARDA’s authority to enter into OTAs would be expanded under the House version of pending legislation.

BARDA has also been willing to use various authorities to enter into public-private partnerships to drive development efforts in non-traditional ways. For example, at the 2015 Industry Day, BARDA introduced the concept of working with an incubator through an OTA to make targeted investments in start-up development efforts relating to antimicrobial resistance. This idea was refined over time and reintroduced at the 2016 Industry Day when BARDA announced details about a new Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator—or “CARB-X”—which is now actively accomplishing similar goals through a cooperative agreement.

DRIVe and Innovative Development

At the 2018 Industry Day, BARDA is expected to continue to focus on promoting innovation with the rollout of DRIVe and programs that will likely be implemented by the new division in the relatively near future. After being in existence for only a few months, the division is already actively working with an Accelerator Network based on the CARB-X model and soliciting proposals for targeted small-scale investments relating to rapid diagnostics, responses to sepsis, and other innovative technologies. In addition, DRIVe is actively making efforts to set up a number of other programs, including:

  • DRIVe Launch, which will likely leverage BARDA’s relatively recent authority to work with a non-profit entity to engage in venture capital practices, including through the use of equity investments;
  • DRIVe Ventures, which is expected to provide similar support through corporate venture capital partners; and
  • DRIVe Fuel Laboratories, which are intended to make co-working laboratory space available to start-up companies with the potential for follow-on investment.

BARDA has indicated that it would like DRIVe’s portfolio to grow over time and ultimately rival that of the Defense Advanced Research Projects Agency.

With DRIVe already in the process of making targeted investments and BARDA’s contracting authority expected to expand by the end of the year, BARDA’s announcement that lightning talks will take place at the 2018 Industry Day presents an exciting and timely opportunity for participants to showcase their development efforts. Similar to the benefits of existing TechWatch meetings, BARDA expects lightning talks to both facilitate discussions with the life sciences community and help the agency with market research necessary to make funding decisions.

Companies that are interested in participating in lightning talks will need to submit applications by September 7 and will be notified during the week of September 24 if they are selected.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Jennifer Plitsch Jennifer Plitsch

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She…

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She has particular expertise in advising clients on intellectual property and data rights issues under the Federal Acquisition Regulations (FAR) and obligations imposed by the Bayh-Dole Act, including march-in and substantial domestic manufacturing. Jen also has significant experience in negotiation and compliance under non-traditional government agreements including Other Transaction Authority agreements (OTAs), Cooperative Research and Development Agreements (CRADAs), Cooperative Agreements, Grants, and Small Business Innovation Research agreements.

For over 20 years, Jen’s practice has focused on advising clients in the pharmaceutical, biologics and medical device industry on all aspects of both commercial and non-commercial agreements with various government agencies including:

  • the Department of Veterans Affairs (VA);
  • the Department of Health and Human Services (HHS), including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), and the Centers for Disease Control (CDC);
  • the Department of Defense (DoD), including the Defense Threat Reduction Agency (DTRA), the Defense Advanced Research Projects Agency (DARPA), and the Joint Program Executive Office for Chemical Biological Defense (JPEO-CBRN); and
    the U.S. Agency for International Development (USAID).

She regularly advises on the development, production, and supply to the government of vaccines and other medical countermeasures addressing threats such as COVID-19, Ebola, Zika, MERS-CoV, Smallpox, seasonal and pandemic influenza, tropical diseases, botulinum toxin, nerve agents, and radiation events. In addition, for commercial drugs, biologics, and medical devices, Jen advises on Federal Supply Schedule contracts, including the complex pricing requirements imposed on products under the Veterans Health Care Act, as well as on the obligations imposed by participation in the 340B Drug Pricing program.

Jen also has significant experience in domestic sourcing compliance under the Buy American Act (BAA) and the Trade Agreements Act (TAA), including regulatory analysis and comments, certifications, investigations, and disclosures (including under the Acetris decision and Biden Administration Executive Orders). She also advises on prevailing wage requirements, including those imposed through the Davis-Bacon Act and the Service Contract Labor Standards.